ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.
Bruna PelliniNadja PejovicWenjia FengNoah J EarlandPeter K HarrisAbul UsmaniJeffrey J SzymanskiFaridi QaiumJacqueline L MuddMarvin PettyYuqiu JiangAshla SinghChristopher A MaherLauren E HenkeHaeseong ParkMatthew A CiorbaHyun KimMatthew G MutchKatrina S PedersenBenjamin R TanWilliam G HawkinsRyan C FieldsAadel A ChaudhuriPublished in: JCO precision oncology (2021)
Tumor-naive plasma ctDNA analysis can sensitively and specifically detect MRD in patients with oligometastatic CRC after neoadjuvant chemotherapy. Urine-based ctDNA MRD detection is also feasible; however, it is less sensitive than plasma because of significantly lower levels. Oligometastatic patients with detectable MRD may benefit from additional personalized treatment based on ctDNA-derived oncogenomic profiling.